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Abstract
This paper is concerned with exploring the implications of replicability issues over the medical
innovation process. Each research setting is characterized by a specific level of replicability, vari-
ability increasing with the complexity of the testing settings. The study introduces new measures
to quantify the research efforts across different medical experimental settings. Doing so allows to
map the dynamics of knowledge along the medical R&D spectrum and over time. The lack of repli-
cability of experiments was overcome by recombining technological knowledge coming from distinct
uses (laboratory tool and other medical applications) with clinical insights. The citation analysis
suggests that science, technology, and clinical learning interact strongly and have an uneven impor-
tance over time. The study stresses the importance of economics of scope between experimenting
and technology developments. In this process, a new type of chemotherapy emerged without a cen-
tralized institution governing the testing efforts. Research and innovation policy implications are
discussed.
Keywords Medical innovation - knowledge translation - replication - instrumentation
JEL Codes: I12 - O31 - D83 - D85
• Replication issues affect the scope of the medical knowledge base
• Replication issues are overcome by the other innovation pathways
• Uneven role played by the innovation pathways over time
• “Testing regimes” can develop without related institution
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1 Introduction
Science moves forward by corrobation: scientists’ aim at challenging the scope of existing results, or
theories. The capacity to replicate research findings 1 is thereby the cornerstone of scientific research.
Put in other words, only if observations present a similar pattern, hypothesis and theories can be
developed in order to explain the laws of nature. Only in this specific case, science can guide our un-
derstanding of a given studied phenomenon.“Despite being a defining feature of science, reproducibility
is more an assumption than a practice in the present scientific ecosystem” (see Errington et al., 2014,
:1). To illustrate this quote, Prinz et al. (2011) report that only 25% of pre-clinical studies in cancer
could be replicated. In 2012, researchers from Amgen delve further into question by publishing a
study describing their failure to replicate 47 of 53 cancer landmark papers (Begley & Ioannidis, 2015).
Even more worrying, the authors of published studies face also difficulties in reproducing their own
studies (Baker, 2016). The relative validity of published results has become an increasing concern for
the scientific community, especially in the biomedical area. Some authors even talk about a “crisis of
replicability” (see Ioannidis, 2005). In this context, science can hardly be expected to guide innovative
efforts through a conscious process of planning and designing (Gelijns et al., 2001).
The debate has focused on the links between replicability and the “publish or perish” culture (i.e.
incentives to publish rather innovative results over replications, inaccurate reporting of methodolo-
gies, and scientific misconducts through the lack of transparency regarding methods, or falsification of
results) (Alberts et al., 2014). However, few studies have investigated the impact of the lack of repli-
cability on innovation. Replicability has been mainly indirectly investigated in the context of building
experimental conditions to make research results predictable (Nightingale, 1998, 2004). Building “ap-
propriate” experimental conditions (e.g. complex enough to reflect reality but in the same time, simple
and controllable enough to learn about a given phenomenon) generates predictable results, which are
used in turn as “operational principles” to innovate (Vincenti, 1997). The capacity to learn through
experiments would be one of the reasons explaining the uneven character of innovation across sectors,
or diseases (Nightingale, 2004; Nelson, 2008; Yaqub & Nightingale, 2012; Yaqub, 2017a,b). Hence, the
limitations (or absence) of experimental conditions to learn about a given technology does not affect
only the rate of innovation but also the direction of innovative efforts (see Nightingale, 2004; Nelson,
2008; Yaqub & Nightingale, 2012). The characteristics of the experimental conditions shape also the
features of specific technological designs (Yaqub, 2017a,b). This study contributes to this stream of
medical innovation literature by documenting how the characteristics of the experimental conditions
affect the dynamic of the medical innovation process over time. The uncertainty coming from the
numerous and competing assumptions about the behaviour the technology is overcome by combining
insights from unrelated technological areas and clinical insights. Consequently, the lack of guidance
from science is responsible for expanding the scope of the knowledge base to unrelated technological
fields (e.g. polymers), to unrelated medical applications (e.g. technological properties accumulated
for non-medical purposes), and other medical complementary technologies. Regarding the limited
fundamental understanding of the problem to solve, the issues related replicability are overcome by
clinical learning. As suggested in Yaqub (2017a), clinical trials are more than a tool to select design
but question the relevancy of the current bodies of understanding accumulated in laboratory settings.
Combining insights from experiments conducted in different contexts of use was the key to overcome
1Performing an existing study in order to confirm its results by independently testing the significance of a given set
of results
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the replicability issues. While the importance of experimental learning and the integration of distant
technological knowledge was mainly investigated in the context of devices and vaccines respectively
(for an overview see Gelijns & Rosenberg, 1995; Consoli et al., 2016), this study shows that the latter
hold in the case of drugs as well. Contrary to the general belief that science guides the translation of
research findings to the clinic, this study echoes Nightingale (2000) who show that testing technologies
more than science influence the rate and direction of innovative efforts in pharmaceuticals. To do so,
the study aims at contributing to the medical innovation literature: i) by introducing new measures to
quantify experimental learning conducted across different contexts (i.e. pre-clinical, clinical settings),
ii) by providing an illustration of the dynamics of feedback mechanisms coming from the different
medical innovation pathways (i.e. science, technology, clinical learning) over time.
The study traces the evolution of a technology - liposomes - which started their career as a research
tool and ended as a new type of chemotherapy. Liposomal research, like cancer research, benefited
from a limited guidance from science due to numerous sources of variations in the lab. In both cases,
the replication of findings was very difficult and did not lead to identify specific mechanisms to let
science guiding technological progress. This case suggests that recombining knowledge accumulated
across different experimental contexts of use was crucial to cope with the radical uncertainty linked
to the disease and the technology. The complex feedback mechanisms between science, technology,
and clinical practice led to a “synthesis of knowledge” which heavily relies on knowledge accumulated
during the initial career of the technology. Despite the absence of an institution governing the coor-
dination and organization of testing activities (see Yaqub & Nightingale, 2012; Yaqub, 2017b,a), the
insights coming from different experimental contexts have been channelled through an instrumental
community (Mody, 2011) which benefited from a certain degree of standardization coming from the
rules of anticancer drug developments. This study shows also that testing regimes can develop in a
more decentralized fashion than what was described in the literature (see Yaqub & Nightingale, 2012),
and adopt the existing rules governing other testing regimes to be standardized. The latter comes at
the price of being less efficient by generating a lot of variations coming from the adoption of testing
rules which are not necessarily fitting the same issues. The paper is structured as follows: section 1
introduces the specificities of the medical innovation process and the background of the case, section
2 details the data sources and methodology, section 3 presents the main results, section 4 discusses
the institutional determinants explaining how the knowledge produced across different experimental
contexts were coordinated, and section 5 summarizes the main findings and limitations of the study.
2 Medical Innovation Framework
Medical technologies, like other technologies, can achieve different functions which can evolve over
time. Technologies fit “artificial purposes” that are imposed to them, meaning that, they are designed
to reach a preconceived end (see Nightingale, 1998, 2004). The functions of technologies are the
results of two main dimensions: on the one hand, the intrinsic properties of the technology which
determine objectively how the technology should behave, and on the other hand, the non-intrinsic
function which is socially constructed, and subjectively specifies how the technology should behave
(Nightingale, 1998). While the intrinsic part is time-invariant, the function of a technology can be
adapted across contexts of uses, or evolves over time. A same technology can thus perform several
functions across different contexts of uses, or users. Nightingale (2004) takes various examples of
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sectors (i.e. pharmaceuticals, combinatorial chemistry, aerospace, software, chemical engineering) in
which innovation lies in adaptating technologies to a given function. To do so, substantial experimental
learning is needed to achieve the desired technological purpose by accumulating knowledge about its
intrinsic properties in different experimental conditions.
2.1 The concept of Testing Regime: learning by experimenting
In the medical context, the experimental demonstration that a technology can achieve a certain pur-
pose establishes its use in medical practice. This process is achieved through an intensive period of
testing activities which is heavily regulated in pre-clinical and clinical conditions. Recent contribu-
tions highlight the difficulties in learning from experiments in preclinical (Yaqub & Nightingale, 2012),
and/or in clinical settings (Yaqub, 2017b,a). Learning in experimental settings requires the capacity
to isolate, to control, and to replicate a given phenomenon (Nelson, 2008). To do so, building an
appropriate infrastructure is needed to observe patterns and to create predictability (see Pavitt, 1998;
Nightingale, 1998, 2004). Yaqub & Nightingale (2012) introduce the concept of “testing regime” to
describe the environment (i.e. the institutional and physical settings - techniques, skills, and context
of experimentation - characterizing a given experiment) in which knowledge is accumulated. Without
appropriate experimental conditions, the capacity to accumulate knowledge about the properties of
a given technology is severely hampered (Yaqub & Nightingale, 2012; Yaqub, 2017a,b). When ex-
periments become stable environments, researchers can study technologies with the aim of providing
scientific answers about their underpinning mechanisms. To stabilize or routinize the research envi-
ronment, the use of specific instrumentalities2 is thereby needed to test different assumptions about
the behaviour of a given technology (Nelson, 2008). By becoming predictable contexts, scientific
explanations are “true”, in the sense that scientific knowledge is used to “match” the function of a
given technology with a desired purpose (Nightingale, 1998, 2004). The fundamental understanding
of the behaviour of a technology can only be investigated when it becomes predictable. In this sense,
technology can emerge and precede scientific understanding (Nightingale, 2004).
2.2 Experimental learning: its consequences on the medical innovation process
The limited fundamental understanding about the interaction(s) of a technology within the human
body explains that uncertainty remains even after its commercialization. The nature of health prob-
lems (see section 3.1) combined with the limitations of the experimental condititons in which knowl-
edge is accumulated reduce the scope of the results predicted in the lab. Therefore, a market approval
does not constitute the end of the journey of a given technology but rather initiates an extensive
learning period in clinical settings (see the post-implementation in Gelijns et al. (1998)). A technol-
ogy can reach the market and then, be modified to refine an existing medical purpose (see the case
of contraceptive pills in Gelijns et al. (1998)) or, to achieve new medical purposes (see for example
off-label drugs in DeMonaco et al. (2006)). In this context, innovation is not linear, initiated in the
lab with scientific knowledge guiding research efforts in clinical trials. Instead, medical innovation
comes from an “original synthesis of knowledge” (Nelson et al., 2011). Relevant knowledge can come
from different institutional contexts (i.e. hospitals, academia, industry), experimental contexts (i.e.
laboratory, pre-clinical, and clinical settings), or non-medical sectors (see Gelijns & Rosenberg, 1995,
for a discussion of the medical innovation knowledge base). Nelson et al. (2011) determine three main
2Beyond physical devices, instrumentalities refer to all models, statistical methods, or protocols used in experiments,
(see deSolla Price, 1984, for more details)
4
sources of insights coming from the contexts previous described: science, technological capabilities,
clinical learning. These three innovation pathways interact through “continuous feedback” over the
innovation process (Gelijns & Rosenberg, 1995). The medical innovation process is thereby defined as
being non-linear, highly complex, and dynamic (Gelijns & Rosenberg, 1994, 1995; Gelijns et al., 1998).
The dynamic and non-linear nature of the medical innovation process is responsible for putting the
locus of medical innovation at crossroads between institutions and disciplines (Gelijns & Rosenberg,
1995; Consoli et al., 2016).
2.3 Testing to adapt functions: From research technologies to new medical devices
The uncertainty previously described is more pronounced in some disease areas (see section 3.1).
Consequently, one way to innovate was to adapt the function of existing technologies to reduce uncer-
tainty coming from the limited understanding of the disease, symptoms, or pathologies. Deepening
the understanding of a pathology by adapting the use of a technology to a medical diagnostic pur-
pose was also an important driver in this process (see von Hippel & Finkelstein (1979) for chemical
analyzers, Spetz (1995) for laser applications, Blume (1995) for cochlear implants, Blume (2002) and
Rosenberg (1992) for MRI). The adaptation of technological functions has been described as a long
process of trial and errors in which scientists at crossroads between institutions and/or disciplines
played a leading role. More specifically, these studies put to the front the role of individuals with a
dual background who are able to: first, align the needs of different actors who do not necessarily share
the same perspective on the design or purpose of a given technology, second, articulate knowledge
from unrelated medical areas (von Hippel & Finkelstein, 1979; Spetz, 1995; Blume, 1995). Another
shared characteristic between these technologies is that they all were developed for research purposes
(measurements in the case of laser and chemical analyzers, modelling internal ear for the cochlear
implants, and spectral scanning in physics for MRI). Due to the nature of research purposes, aca-
demic researchers played a leading role in this process, not only by diffusing the use of instruments to
industry (Rosenberg, 1992) but also creating new medical uses with the help of medical practitioners
(Rosenberg, 2009). While initially used as laboratory apparatus, a long process of experimenting was
used to adapt these technologies to a medical function to end their “career” as a medical technology
(Blume, 2002). Blume (2002) defines the “career of a medical technology” as organized around four
main steps: exploration, development, diffusion-assessment, and the feedback stages. After finding how
and why a specific medical function can be achieved, the medical and industrial communities focus
their efforts in demonstrating the feasibility of the new function to achieve. The diffusion-assessment
phase is more oriented towards medical communities, who specify and legitimize the use of a given
technology in medical publications. Finally, over the last stage, improvements of the first design are
determined after an extensive of use of the technology in clinical settings. The medical and industrial
communities work hand in hand to refine the first technology design. In each step, the technology
is shaped and reshaped while the locus of R&D efforts gradually shifts between academia, industry,
and hospitals (Blume, 2002). This process of refinement takes place within an interorganizational
structure (Blume, 2002) which coordinates efforts to avoid their fragmentation. The results will fol-
low a similar structure as the “career” steps described in Blume (2002) and section 6 will discuss the
enabling factors responsible for creating an interorganizational structure.
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3 Contextual background
3.1 Cancer: the limited power of science
Human body is a complex system consisting of billions of cells, molecules, and biochemical processes.
Likewise, deepening the fundamental mechanisms related to a given disease requires unravelling the
complexity of human body. This implies being able to identify the role(s) and the various interactions
between multiple pathways (i.e. gene, proteins, and cells) (Dougherty & Dunne, 2012). Cancer is not
an exception to this rule. The disease is known and has been described since the Ancient Greece. Its
name comes from the word karkinos which refers to the crab-liked pattern that characterizes cancerous
cells development. Cancer is defined as “an abnormal cells divide without control and that can invade
nearby tissues” (National Cancer Institute website3). While initially put under the same umbrella,
scientific progress suggested that different types of cancerous diseases exist and emerge as a result
of genetical and/or various environmental factors. Despite significant progress in genetics (Fujimura,
1988; Faguet, 2008), cancer remains a disease area where the emergence of solutions is still limited.
The nature of the mechanisms, like most of health problems, is thereby defined by a high degree of
complexity, dynamism, non-linearity, and interdependencies (West & Nightingale, 2009). Reducing
the complexity of cancer-related problems by breaking them into a set of independent sub-problems,
like in engineering, is still limited.
The difficulties related to studying health problems in the lab are also the result of clinical variability
(Gelijns et al., 1998; Ali & Gittelman, 2016): a given cancerous form affects people differently. Put
in other words, the predictions from the lab are relevant at best for a sub-sample of the patients.
For example, progress in genetics initiated the development of targeted therapies. The latter, based
on predictions made by algorithms about gene expressions, does not necessarily take into account
their variations across patients. While having enthusiastic results in the lab, clinical trials failed
for having underestimated ethnic variations (Duconge et al., 2015). This example illustrates the
“weak-predictability” argument developed by Pavitt (1998) and Nightingale (2004). Considering this
radical uncertainty about the mechanisms underpinning cancerous processes, science has a limited
guidance on technological progress. As developed below, technological progress in this disease area
tends to precede scientific understanding and its rate increases with improvements coming from testing
activities.
3.2 Radical uncertainty and consequences on innovation
Chemotherapy emerged as the paramount solution against cancer. Even if different clinical options can
be used (i.e. radiotherapy, surgery, immunotherapy and target therapies in some cases), chemotherapy
is usually used in combination with other modalities. Cancer chemotherapy emerged in the 1960s as
a result of a substantial testing campaign ran in the 1950s. However, the fundamental understanding
of the chemical compounds effects on the DNA of cancerous cells was suggested only in the 1970s
(DeVita & Chu, 2008). The idea of using chemical compounds to treat patient came from experimental
observations linked to the use of Mustard gaz during WWI and WWII. Over WWI, military doctors
observed the destructive power of mustard gas on cells from the bone marrow (Faguet, 2008). These
preliminary observations were extended by the consequences of the bombing attacks in the harbour of
Bari (Italy). The illegal possession of Mustard gaz among US navy boats spread massive amounts of
3https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cancer
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chemicals around the region of Bari in Italy4. The first observations from WWI were hence confirmed
by this second episode which reinforced the idea of using chemical compounds to treat cancer. This
idea paved the ground to the so-called “cell-kill” paradigm (Faguet, 2008).
In absence of scientific understanding, technology was offering an avenue: destroying the cancerous
cells before letting them overwhelming the patient. However, defining the appropriate compounds
and dosage in order to develop a medical solution required tremendous testing efforts. This unique
testing campaign benefited from the support of a dedicated institution, the National Cancer Institute,
established in 1971 when the Nixon’s administration launched the War on Cancer (for more details
about the testing campaign Faguet, 2008; DeVita & Chu, 2008). This testing campaign created the
need to develop evaluation standards in testing activities: it gave birth to statistical procedures to
assess the risks and benefits of the chemical compounds in clinical trials (Keating & Cambrosio, 2007).
Over time, new guidelines and rules were developed and refined in pre-clinical and clinical settings
as well (see section 6 for more details). However, without a fundamental scientific understanding
of the effect of chemical compounds on cancerous cells, tumor-shrinkage remains the standard to
evaluate the treatment success (Faguet, 2008). Advances in screening technologies led to economics of
scale and scope in testing (see for an illustration Thomke et al., 1998; Nightingale, 2000) which helped
detecting molecules but without guaranteeing their efficacy after leaving the lab (see the “hit and miss
approach” described in Faguet (2008)). The serious side-effects related to the use of chemotherapy
represented a barrier to adopt the latter among practitioners5. In absence of therapeutic alternative,
chemotherapy entered the oncologist armatorium but the idea of using “a magic bullet” (Himmelweit
et al., 1960) remained in the head of the medical community in order to foster the therapeutic benefits
and to decrease the side-effects.
3.3 Liposomes: from the lab to the clinic
Liposomes refer to a nano-structure which is similar to a little bubble. Their discovery comes from the
observations of horse blood cells by two hemaetologists at the Bangham Institute in 1961. By testing
the electronic microscope recently acquired within their laboratory, Bangham and Horne could better
observe the structure surrounding the blood cells. The pictures coming from the electronic microscope
put an end to a long debate in the field of biology in which the structure of the cell membrane was still
heavily discussed. The importance of this finding has been compared to the impact of the DNA double
helix structure in the field of life sciences (Deamer, 2010). Consequently, this finding attracted the
attention of scientists from numerous fields beyond cell biology (i.e. physiology, biophysics, physical
chemistry, molecular biology)6.
3.3.1 Liposomes as a research technology
Bangham and Horne, in collaboration with other biophysicists, established the chemical and physi-
cal properties of such structure and coined the term of “liposomes”. In 1965, Bangham developed a
method to produce artificially liposomes. Considering their proximity with cell membranes, liposomes
4Considering the Geneva treaty, the use of chemicals was forbbiden. For more details about this event, see (Faguet,
2008)
5As described in DeVita & Chu (2008), the first medical practitioners who used chemotherapy against cancer were
called “butchers” by their peers
6Mody (2011) underlines the proximity and porosity of these fields in the 1960s and the use of similar apparatus
(microscopy techniques) eased the dialogues between these fields
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were hence initially used in the field of membrane modelling to test various properties (e.g. how
does the cell membrane reacts with changing pH, temperature). Liposomes started their career as
a research technology, or “instrumentality” (deSolla Price, 1984). Therefore, by being at the core
of experiments to test scientific assumptions about cell behaviour, numerous knowledge about the
technological properties of liposomes was accumulated in biophysics, physical chemistry, and even
biomolecular engineering. However, building a strong body of science was hampered by numerous
variations in experimental settings. First, liposomes can be synthesized by using various chemical
formulations, creating a lot of variations in designs. Second, besides the inputs, the sequence of pro-
duction steps also influences their properties (Wagner & Vorauer-Uhl, 2011). Put in other words, the
chemical inputs used, the methods, protocols, and bodies of practice involved in their production were
responsible for changing their technological features. Consequently, the accumulation of knowledge
about their technological properties was bounded to the specificities of their designs and production
methods, giving a limited scope to the results generated in the lab.
3.3.2 Liposomes as drug delivery systems
The career of liposomes took a different direction very early due to the involvement of young re-
searchers in clinical research. After the liposomes discovery, Gregory Gregoriadis who was finishing
his PhD in biochemistry decided to visit Bangham’s laboratory. Trained in animal work and test-
ing, his background helped to connect the founding fathers of the liposomal field with the medical
community (Gregoriadis, 2018). Bangham and his colleagues, like Gregoriadis, were convinced that
liposomes could encapsulate drugs. The first step towards medical applications of lipsomes as delivery
systems was made when Gregoriadis joined the Royal Free Hospital in 1971. He collaborated with
Brenda Ryman on the first medical application of liposomes7. After this demonstration that liposomes
could be used as a carrier, a dedicated research group involved in clinical settings was established at
the Charing Cross Hospital School of Medicine (Gregoriadis, 2018). This group was responsible for
demonstrating that liposomes could be used as drug delivery in patients by using liposomes as im-
munological adjuvant (Allison & Gregoriadis, 1974). The latter established the career of liposomes
as drug delivery systems. A following successful therapeutic application against Gaucher’s disease
reinforced the vision related to this new function (Gregoriadis, 2018).
These clinical successes “crystallized” the expectations related to liposomes across a wider range of
researchers. Consequently, the demonstration of their potential as drug delivery systems attracted an
increasing amount of researchers, from a larger set of scientific and medical disciplines (Gregoriadis,
2018). However, the development of medical applications of liposomes was plagued by the limited ca-
pacity to accumulate technological knowledge. By becoming a medical technology, liposomes entered
more complex conditions (e.g. pre-clinical and clinical settings) than the settings characterizing their
use as a research technology. The issues linked to the replication of experiments were exacerbated by
the sources of variations coming from the type of loaded chemical compounds and the variations in
the models used (e.g. type of cells involved in in vitro testing, animal models, anticancer compounds).
The loaded chemical affecting the properties of a given liposome formulation, it was difficult to iden-
tify the causes explaining the variations observed across experiments (i.e. the loaded substances,
the formulations and related production methods, or the experimental conditions). Despite all these
difficulties characterizing the R&D efforts, the first US market approval in cancer chemotherapy was
7Liposomes were first used as a way to deliver glycogen into the liver to fight against a child disease
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made in 1995. The next sections investigate how the liposomal community overcame these replication
issues to adapt the function of liposomes.
4 Methodology
Citation network analysis has been the reference method to understand the dynamic of medical
innovation knowledge (Mina et al., 2007; Consoli & Ramlogan, 2008; Barberá-Tomás et al., 2011).
In this regard, the Main Path algorithm has been identified as an appropriate way to observe the
main sequence of medical problem-solving (Mina et al., 2007; Consoli & Ramlogan, 2008; Barberá-
Tomás et al., 2011). This trajectory depicts an emergent knowledge space, in which knowledge is
accumulated in a path-dependent fashion. The trajectory reflects the set of relevant problems to solve
and the solutions that prevail (Metcalfe et al., 2005). The analysis of the patent and publication maps
is cross validated by several historical reviews (mainly Weinstein, 1987; Gregoriadis, 1989; Barenholz,
2012; Allen & Cullis, 2013). Two experts in the field, Prof. Theresa Allen8 and Prof. David Deamer9,
who were both involved in patenting and publishing over the investigation period has checked the
main sequence of problem-solving. The next subsection explains in details the assumptions made on
the citations and how they are used to delineate the most important developments. This study aims
at going a step further than previous medical studies (see Consoli et al., 2016, for a recent overview)
by representing the knowledge flows across science, technology, and clinical learning (see subsection
4.2).
4.1 Assumptions about the key trajectories
The Main Path analysis constructs a knowledge space which can be organized in layers. Like in
genealogy, each layer represents a generation of knowledge reflecting the scientific, or technological,
state of art related to a given period. The time dimension is considered in a historical manner rather
than in a continuous span fashion (Metcalfe et al., 2005): the introduction of new techniques, or
new observations, modifies structurally the accumulation of knowledge and is reflected within the
dynamics of citations. Thereby, the identification of each generation of research efforts is based
on their structure. The analysis is performed in two steps: first, the network is structured in layers
thanks to the Search Path Count method, then, the algorithm identifies the most important knowledge
pieces based on the previous step. In this context, a node refers to a piece of knowledge (patent or
publication) and a citation represents an arc linking two nodes.
4.1.1 The Search Path Count: defining the structural properties of the network
The Search Path Count method has been developed by Batagelj (1991) and is available on Pajek
software 10. This procedure relies on a previous approach elaborated by Hummon & Dereian (1989).
Hummon and Dereian develop and compare different methods to assess the importance of a node
within a given network. The Search Path Count seems to be the most efficient method, and is the
8Theresa Allen is one of the pioneers of lipid-based drug delivery and made ground breaking contributions to the
development of liposomal anti-cancer drugs. In this regard, she participated in the development of the approved liposomal
anti-cancer drug, DoxilR©.
9David Deamer is a biophysicist who built his career on the field of lipids after a sabbatical in Bangham’s laboratory in
1975 after the liposome discovery. The latter applied his knowledge about lipids in a more basic fashion by investigating
the role of the cell membrane in the origin of life.
10http://mrvar.fdv.uni-lj.si/pajek/
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least dependent approach regarding the network size (Batagelj, 2003). First, the Search Path Count
detects all vertices that are “sources” (nodes which only cite) and “sinks” (nodes which only receive
citations) according to the structure of citations. The algorithm computes the total number of paths
between all sources and vertices based on their respective citations. Then, the algorithm assigns a
value to the different paths by measuring the number of times a given path is followed. The frequency
of passing through a given path is determined by the structure of the citations within the network.
This step defines the transversal counts of the arcs between the different nodes. The latter are then
used in the identification of the Main Path.
4.1.2 Identifying the main trajectory of interest
The main path (MP hereafter) analysis simplifies the sequence of problem-solving that faces the
medical actors over time. The related algorithm is available on Pajek. The MP algorithm identifies
the highest weights among the different paths described in the previous section to detect the most
important pieces of knowledge. When the largest transversal is found, the algorithm selects the arc
with the highest weights in its neighbourhood. The algorithm processes backward, starting from the
latest period, until reaching the earliest period. The implicit assumption is the following: “a citation
that is needed in paths between many articles [patents] is more crucial than a citation that is hardly
needed for linking articles [patents]” (Nooy et al., 2011, p.282). The MP is supposed to reflect the
most important junctions of knowledge, assuming that knowledge flows through citations.
4.1.3 The Main Path algorithm: limitations and extensions
Despite its popularity in innovation studies (Mina et al., 2007; Leydesdorff & Schank, 2008; Fontana
et al., 2009; Barberá-Tomás et al., 2011; Martinelli, 2012; Epicoco, 2013), the MP approach repre-
sents an oversimplification of the main developments and provides a very narrow-focused perspective
about the main developments of a given field (Liu & Lu, 2012). This extreme simplification can be
overcome by relaxing the maximization approach: the extended version of the MP (main subnetwork
or self-organized map) contains important pieces of knowledge which are ignored by the maximization
approach. This extended version underlines the different paths explored to solve a given problem,
such as dead-ends or variations of solutions, which are on average less cited. In this study, a threshold
of 0.02 for publications and 0.003 for patents have been used. The key publications and the list of
patents used for the interpretation of the results are available in appendix.
4.2 Data: crossing patents and publications
Publications and patents are jointly crossed to analyze how the issues of replicability influenced the
fundamental understanding of the new function of liposomes and the related technological problem-
solvings. The analysis differentiates the characteristics of the testing conditions in which a cited piece
of knowledge was generated. On the one hand, the sources of variability increase along the spectrum
of R&D, multiplying the chances to lead to unreplicable results. On the other hand, the degree of
relevancy characterizing the testing settings more downstream increases and aim at capturing the
complexity of the human body, relaxing the simplifying assumptions made initially in the lab. This
degree of sophistication characterizing the context of experiments comes at the expense of increasing
sources of variability (see Figure 1).
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Figure 1: Delineating the context of experiments
This methodology assumes that the prior art reflects the accurate sources of knowledge involved
in solving/answering a problem/scientific question. Doing so captures and maps the dynamic of
feedback mechanisms coming from different experimental contexts over time. The delineation is based
on publication information and is computed at the publication level. Regarding patents, the analysis
crosses author-inventors’ names in order to measure to which extent problem-solving relies on insights
from experiments. As mentioned in section 3.3.2, liposomes were initially used as research technologies
and numerous properties about their behaviour were accumulated. This knowledge represents thereby
interesting depositories of knowledge to adapt the function of liposomes. Moreover, clinical learning
might have been as well necessary to overcome the radical uncertainty coming from misleading results
in the lab. Distinguishing the relevant sources of knowledge helps to see how replicability enlarged
the scope of the knowledge base and influenced the type of knowledge recombination over time.
The sample is bounded to the USA, e.g. US granted patents, and publications with at least one
author affiliated to the USA. The choice to focus on one country is mainly justified by the importance
of national institutions within the health sector (Consoli et al., 2009). The USA represents the largest
market for medical innovation and the biggest player worldwide of cancer R&D efforts11. Finally,
focusing on granted patents only help focusing on the most significant technological milestones over
time.
4.2.1 Delineating the context of experimental knowledge
Scientific publications constitute the main channel of communication for scientists and physicians
to share their respective experience and advances. PubMed and Web Of Science are combined to
maximize the amount of information between both data sources. Publications that only deal with
liposomes research efforts in cancer were considered. To do so, publications were selected from PubMed
based on Medical Subject Headings (MeSH) which bound the sample to the use of liposomes in the
field of cancer (see appendix)12. The related set of PubMed-Indexed for MEDLINE (PMID) was used
to collect the citations and full affiliations information from the Web of Science13. Cited references
were extracted based on their DOI information and used to extract their related PMID on PubMed
and Web of Science. Doing so allows to differentiate the context of knowledge production and citation
over time14.
To delineate the different empirical settings, the main MeSH terms and the publication types available
on PubMed have been used. The publication types are used to define the more downstream conditions
11The National Cancer Institute represents the largest funder worldwide, see https://www.cancer.gov/research/
nci-role
12Only one keyword (“Enhanced Permeability Retention”) was not available within the MeSH classification and was
added considering its importance within the developments of liposomal chemotherapy (Weinstein, 1987).
13The data was collected in November 2014
14Due to data limitations linked to the availability DOI/PMID in the 1970s, Figures 4 and 5 start in 1973 and not
1972
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(in vivo preclinical testing and clinical settings) (see Table 4 in appendix). The more upstream settings
(laboratory settings vs experiments in vitro) are distinguished based on the main MeSH. In this case,
the publication type could not differentiate between the old and the new function of the technology.
Therefore, a specific set of MeSH terms related to their initial purpose in cell modelling was used (see
Table 4 in appendix for more details). Publications that did not fit any criteria are defined as part
of upstream science, or non-experimental knowledge. This assumption implies that research efforts
which are less oriented towards testing specific liposomes properties do not belong to any “testing
regimes” (Yaqub & Nightingale, 2012).
0
500
1000
1500
1970 1980 1990 2000 2010
Year
P
ub
lic
at
io
n 
co
un
t
Figure 2: Quantity of publications over time
(non-experimental knowledge)
0
50
100
1970 1980 1990 2000 2010
Year
P
ub
lic
at
io
n 
co
un
t
ClinicalPractice In vitro In vivo
Figure 3: Quantity of publications over time (ex-
perimental knowledge)
0
20000
40000
60000
1973                                                                                                     1987                          1991                1995                    1998                                       2006                                                        2014       
Year
Fr
eq
Figure 4: Number of citations over time (non-
experimental knowledge)
0
500
1000
1973                                                                                                 1987                                                 1995             1998                                                       2006                                                    2014 
Year
Fr
eq
invivo invitro CP
Figure 5: Number of citations over time (experi-
mental knowledge)
The sample is composed of 22683 publications which covers the period from 1972 to 2014. With
their respective references, the network is formed by 500864 nodes and 1030630 arcs connecting them.
Figures 2 and 3 display the growth of publications according to the context in which knowledge has
been generated (in vitro, in vivo, clinical or laboratory settings without specific experimental orien-
tation). Figures 4 and 5 describe the number of citations belonging to different experimental settings
(laboratory settings without applied purposes vs experimental testing). References to publications
without specific and applied liposomes purposes dominates the citation dynamics over time, limiting
the use of share of citations to characterize the citation patterns. The first period, from 1972 until
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the 1980s, is marked by producing and using knowledge mainly generated upstream or in vitro. This
fits with the initial purpose of liposomes as membrane models. The second period (1980s until 1997)
shows that the production of knowledge increases across all settings but the use of knowledge seems
to be concentrated rather upstream (non-experimental and simplified testing contexts, in vitro and
in vivo). A break emerges around 1997: the production and use of non-experimental knowledge de-
creases substantially before increasing again in 1998. Moreover, the use of experimental knowledge
seems to play a role right after the market approval in 1995. This changing dynamics illustrates the
concept of the post-implementation period (Gelijns et al., 1998): the extended use of the technology
in clinical settings stimulates the need for new scientific explanations about unexpected phenomenon
and additional improvements of the existing technology. In this study, the observation in 1998 that
liposomes did not cluster around cancerous cells after the first accelerated market approval in 1995
required new scientific understanding, explanations, and new improvements about this phenomenon
(see the next section for more details). The different trends suggest that citation counts might be
misleading to understand the impact of replicability on innovation efforts and that more qualitative
insights are needed.
4.2.2 Delineating the sources of technological developments
Liposomes are defined by their chemical formulation which makes patents a relevant mean of knowledge
appropriation (Pavitt, 1984), and an useful measure to understand the evolution of problem-solving
over time. Patents have been extracted if their main, or one of their secondary, technological class(es)
refers to 424/45015. This technological class refers to the physical definition of liposomes (lipid bi-
layers) related to pharmaceutical preparations. The use of patents coming from secondary classes is
necessary to take into account the migration of technological capabilities within the medical arena
(see Rosenberg, 1992; Spetz, 1995; Rosenberg & Gelijns, 1995). Two different sources of patent data
are crossed to increase the amount of information: the NBER database16 was used to obtain the
patent assignees and the Harvard Dataverse database17 (Lai et al., 2015) is used to retrieve the patent
sample, the respective patent prior art, and the standardized inventors’ names. 2397 patents form
the sample, covering the period 1975 to 2006. The patent network is composed of the set of selected
patents and their respective references (10440 nodes in total) and is connected by 30798 arcs. The
quantity of patents increases slowly over time until it shows a peak in 1998; 3 years after the first
accelerated market approval in the USA. The decline of granted patents that occurred in the 2000s
is linked to a boom of spin-off technologies (Mozafari & Khosravi-Darani, 2007). The latter changed
the definition of liposomes as lipid bilayers and their belonging to the 424/450 class. 1063 patents
belong to the primary class defining liposomes as carriers of pharmaceutical preparations while 1334
patents refer to the latter as one of the secondary classes. Table 1 summarizes the distribution of
the primary technological class for the patents which refer to liposomes as a secondary class. Overall,
these patents cover 42 primary classes at the 1-digit level18. As expected, the majority of the applica-
tions that involve liposomes is on average about health care. However, the scope of the technological
classes underlines the generic aspect of the technology.
15Only granted patents are considered to focus on relevant patterns of citations. Some noise could emerge from the
analysis if some “weak” patents were cited for other reasons (e.g. increasing the value of a firm’s portfolio)
16available online https://sites.google.com/site/patentdataproject/Home/downloads
17available online https://dataverse.harvard.edu/dataset.xhtml?persistentId=hdl:1902.1/15705
18The table reports only the classes which represents more than 1% in the sample.
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Table 1: Distribution of the primary classes for patents using 424/450 as a secondary class
Definition Class Share
Drug, bio-affecting and body treating compositions 424 53.09%
Material or article handing 414 21.51%
Chemistry: molecular biology and microbiology 435 7.22%
Plastic and nonmetallic article shaping or treating: processes 264 4.74%
Chemistry natural resins or derivatives; peptides or proteins; lignins or reaction products thereof 530 2.84%
Stock material or miscellaneous articles 428 2.04%
Organic compounds 536 1.02%
The multi-purpose aspect of liposomes to carry various substances has been exploited across a
wide range of applications beyond medical ones (i.e. cosmetics, analysis, dietetics). Table 2 indicates
the share of patent ownership within the sample19. It provides some insights about the leading role
played by firms and US research institutes within the technological efforts. Besides, the importance
of foreign firms is explained by the presence of many multi-national firms (Schering, Novartis, Fugi
Photo, Bayer, L’Oreal) among patent assignees who exploited the multi-purpose aspect of liposomes20.
US universities and institutes represent important patentees, in line with the initial purpose of lipo-
somes applications. However, US hospitals and medical institutions represent a small patentee. To
see whether pre-clinical and clinical learning played a role in solving technological problems, the next
section goes at the author-inventor’s level and applies the same publication delineation previously
described. Doing so disentangles between two sources of economics of scope in solving technolog-
ical problems: learning by experimenting (as research tools or medical technologies) and scientific
investigations more upstream where testing their properties was not at the core of the investigation.
Table 2: Share of patent ownership (fractional count)
Assignee type Share
US corporation 36.15%
Foreign corp. incl. state-owned 30.36%
US institute and university 17.24%
Individuals (US and foreign) 7.34%
Foreign institute and university 4.87%
US and US state government 1.80%
Foreign government 1.44%
US hospital/med inst 0.80%
4.2.3 Defining the relevant sources of learning to solve technological issues
Focusing on patent assignees, or technological classification, limits the capacity to explain which
type(s) of knowledge were needed to solve technological problems. Inventors’ names are therefore
used to track related publications in the field of liposomal chemotherapy. The full set of information
between Pubmed and the Harvard Dataverse was joined by crossing the first name, middle initial,
and author-inventors’ surname (see Azoulay et al., 2009, for a similar approach). A time-window of
19432 patents had a dedicated pdpass but did not refer to a specific assignee code within the NBER database. Crossing
inventors and assignees’ names, this set of patents turns out to be held by inventors is coded as individuals in Table 2
20Numerous Israelian start-ups played a leading role in providing technological capabilities to the first market approval
related to liposomal cancer chemotherapy, see his review Barenholz (2012) about DoxilR©
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two years maximum before, or after, for a given pair of patent application(s) and publication(s) is
used to take into account inventor mobility21. Three types of inventors are defined: inventors without
related publications, author-inventors who published without specific experimental purposes linked to
liposomes, author-inventors who published studies related to the use of liposomes as research technolo-
gies and/or medical technologies. 1022 distinct author-inventors patented from 1070 to 2005 and are
related to 1405 different patents. The results being aggregrated at the patent level, 2954 publications
could be linked to the patenting activities of author-inventors. Figure 6 shows that author-inventors’
contributions follow a similar trend as the ones depicted by inventors without publications until the
market approval: the intensity of inventive efforts from inventors without publications increases and
decreases faster than their peers publishing. The match between Web of Science and PubMed does not
allow to determine the complete set of affiliations for all author-inventors but suggests that author-
inventors are rather belonging to public research institutes, who reacted less strongly to the market
incentives created by the approval of Doxil. Even if the propensity to patent is similar, the growth of
inventors follows the same dynamic as the one characterizing the patent applications. It also suggests
that the author-inventors represented a small share of the inventors’ population over time but con-
tributed to almost 50% of the overall patenting efforts. Figure 7 reflects a similar trend among the
two types of inventors who both faced a peak of inventing activity when the first accelerated market
approval was launched.
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To ease the interpretation of the citation network and to take into account the unbalance between
publications very upstream and more downstream (e.g. learning by experimenting), only these two
categories have been considered. If multiple publications were found for a given team of inventors, the
publication with the most complex setting - experimental ones - has been considered. By considering a
hierarchy between learning by experimenting and scientific knowledge, the number of publications was
reduced to 1790: 996 patents were linked to a scientific publication, 24 patents linked to a publication
linked to learning by experimenting only, and 385 patents having a combination of both and were
categorized as benefiting from learning by experimenting. After conducting the main subnetwork
analysis, merging the list of the patents from the subnet network led to the following partition: 139
patents were not related to publications, 65 patents were associated to publications related without
experimental purposes, and 22 patents could be linked to publications with experimental purposes.
21Having a time-window before or after the patent application allows to take into account different strategies to
diffusing research results which might differ across actors and sectors
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5 Results
The respective trajectories are composed of 24922 patents and 173 publications. Figure 8b maps the
main technological trajectories over time whereas Figure 8a displays the evolution of the fundamental
understanding related to the use of liposomes as a medical technology. The key publications and
patents composing the Main Path analysis are available in appendix. Both maps are organized in
generations of research efforts: the first stream of research efforts lies at the bottom of the map whereas
the latest developments are located at the top of the maps, the arrows pointing in the direction of the
citation. The size of the nodes is defined according to their relative importance within the network
23.
5.1 Difficulties of R&D and recombination of knowledge
Figures 8a and b depict similar problem-solving based on the abstracts of patents and publications
(see Table 3). Their overlap illustrates the economics of scope that existed between experimental
learning (in laboratory, or clinical settings) and technological developments. The importance of eco-
nomics of scope between technology and learning through experiment across different contexts of use
is also underlined by the importance of author-inventors over time. Figure 8a depicts a sequence
occurring within the sources of feedbacks mechanisms (i.e. pre-clinical, clinical, and laboratory set-
tings). Figure 8b reflects a similar dynamic but seems less neat than Figure 8. On the one hand,
clinical learning plays an important role in solving problems where other complementary medical
technologies are involved (see subsection 5.2.2), and on the other hand, the role of experimental
learning is probably underestimated at the beginning of the period due to data limitations24. The
evolution of technological knowledge relies on two distinct trends: on the one hand, pharmaceutical
developments which take their root in chemical related knowledge, and on the other hand, medical
applications unrelated to chemotherapy (i.e. vaccines, immunoassays, and diagnostic tools). The links
with non-pharmaceutical applications eased to solve different numerous technological bottlenecks (re-
sistant formulation, improved encapsulation methods) in the context of anticancer chemotherapy. The
integration of technological knowledge coming from other medical applications helped to accumulate
knowledge about liposomes behaviour in more complex settings (i.e. animal models and human body).
2212 patents have been removed from the map because they formed dyads of patents disconnected from the main
trajectories, limiting their interpretations in the network
23The algorithm sums the different line values linking a given node to the rest of the network but does not reflect the
number of citations received by a patent
24Some data limitations can explain these differences at the beginning of the analysis NBER and Dataverse start in
1975 and their respective citations go back to the 1950s. Without having standardized inventors’ names, the probability
of finding them within the publication sample was even more reduced. The latter are responsible for underestimating
the role of science and experimental learning on solving technological problems at the beginning of the period.
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Table 3: Main sequence of problem-solving
Cluster Description
A Accumulation of knowledge in vitro and in vivo
B Polymer
C Clinical trials (design 2)
D New uses of design 2
E Immunoliposomes (active targeting)
F New designs, therapeutics and/or diagnostics
5.1.1 Exploration phase: establishing the feasibility of the solution
Liposomes were first used as a tool and did not require a strong stability to achieve this type of
purposes. Their initial function was to mimick cell membrane and played the role of scientific models
(see node 4 and 6 on Figure 8a). Establishing liposomes as cell membranes led to numerous empirical
investigations across disciplines (biology, physics, and chemistry). The role of liposomes as a research
tool was extended by a second type of scientific applications, e.g. carriers to detect substances (see
the immunoassays cluster on Figure 8b). The latter was not impeded by issues related to stability
and benefited from the knowledge linked to loading methods accumulated during the first medical
application of liposomes (represented by the application in vaccine on Figure 8b and described in
section 3.3.2). By remaining a research tool, liposomes stayed at the core of experiments to detect
the presence of various chemical and biological compounds (see for a review Gómez-Hens & Manuel
Fernández-Romero, 2005). This increasing burst of applications linked to the detection of substances
in laboratory settings laid the foundations for applications as diagnostic tools. By being introduced as
diagnostic tools, knowledge about liposomal behaviour coming from in vivo and clinical conditions was
also accumulated and new properties could be checked in more complex settings. In this context, the
use of liposomes as protein carriers laid the groundwork for the concept of cancer “passive targeting”
(Matsumura & Maeda, 1986). The in vivo observations that liposomes were clustering around the
tumour cells rationalized the use of liposomes for cancer chemotherapy and stepped up the research
efforts (Weinstein, 1987; Allen & Cullis, 2013). Matsumura & Maeda (1986) coined the term of
“Enhanced Permeability Retention” to describe the agglomeration of liposomes at the tumour site.
Even if the potential of liposomes was established, the lack of replication represented a huge burden
for the liposome community by limiting the explanatory power of experiments as if it was “impossible
to make definitive experiments” (Weinstein, 1987, p.290). Differences in animal models represented
another source of variation responsible for making the experiments linked to the design of liposomal
chemotherapy as “to some extent heterogeneous and irreproducible” (Weinstein, 1987, p.290). The
limited capacity to replicate experiments impeded the identification of the underpinning scientific
phenomena explaining why some formulations succeeded, or failed. The variability of results was
also exacerbated by the numerous communities involved in solving technological bottlenecks, who
used distinct approaches and apparatus. Science could not guide innovation efforts but the bodies of
practice learnt in experiments represented a source of insights to solve technological bottlenecks. The
issue of replication is also represented in the cluster 3S on Figure 8b in which numerous competing
formulations developed by author-inventors in upstream settings co-evolve. This trajectory required
insights from more complex settings and benefited from a better understanding of liposomes behaviour
from the areas of diagnostics (see the cluster of encapsulation methods on Figure 8b). The development
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of improved encapsulation methods in the field of diagnostics allowed to incorporate drugs in liposomal
formulations which showed being resistant enough to be used in vivo. However, the commercial
potential needed to be demonstrated in order to achieve a market approval.
5.1.2 Development phase: Recombining knowledge from the liposomes initial career
Despite the in vivo demonstration that liposomes could become a chemotherapeutic tool, commercial
objectives also needed to be fulfilled especially regarding the reduction of the production costs. The
search process has been concentrated around 3 main problems: stability, sterility, and scaling-up
methods (see the related cluster on Figure 8). First, a formulation known as “conventional liposomes”
emerged which was the result of combining knowledge from in vivo experiments with early insights
from in vitro research, suggesting that cholesterol was fostering liposomes resistance (see Design 1
on Figure 8b and cluster A on Figure 8a). The first design adapted to chemotherapy relied on using
of cholesterol, like an “operational principle” coming from the first career of liposomes (Vincenti,
1997). This explains why author-inventors more upstream in research settings played a leading role in
adapting this principle observed in pre-clinical experiments. Adapting observations from experiments
accumulated during the first career of liposomes but also bodies of practice constituted ways to
solve technological issues to cope with the replication issues. By considering liposomes as “subjects
of experimentation”, underpinning properties related to their behaviour in simplified conditions led
to accumulate bodies of practice (Nelson, 2008). A small “latent stock of knowledge” remained
embodied into the individuals who performed the experiment (Agrawal, 2006). More precisely, the
experimental design, protocols, and methodologies involved in liposomes experiments constituted a
source of inspiration for potential solutions. For example, some methods used to split liposomes
in microbiology to break cells with a French Press were then adapted to solve industrial problems
(Wagner & Vorauer-Uhl, 2011). After solving the main technological bottlenecks(see the 3S cluster
on Figure 8b), the efforts related to therapeutic purposes intensified and led to different trajectories.
In parallel to this new trend in building pharmaceutical formulations, the diagnostics trajectory led
to numerous applications in order to use liposomes to target specific cell markers. As mentioned
above, the lively interest across distinct scientific communities related to liposomes as a research tool
generated basic knowledge across a wide scope of scientific areas: pH gradients, immunology, and
cell behaviour (Weinstein, 1987). In this context, the idea of binding liposomes to target specific cell
markers emerged from their use as diagnostic tools. Doing so, new methods of production and designs
were developed by inventors acting rather upstream in the lab who benefited from scientific insights
linked to the use of liposomes as research tools. The next section shows the importance of clinical
learning in redirecting the efforts in more promising scientific and technological areas.
5.2 The regulator-user interface
In the context of vaccines, Yaqub (2017b,a) underline the importance of learning in clinical settings
to determine which technological features work in “real” conditions, eliminating the noise coming
from the simplification made in the laboratory settings. Clinical learning plays hence a crucial role
in re-directing scientific and technological searches. The next sections extend what is suggested in
Yaqub (2017a) by illustrating that clinical trials constitute an opportunity to accumulate knowledge
beyond the selection of technological designs. The difficulties characterizing the R&D efforts in the
lab previously mentioned were responsible for creating a weak design, like in the case of vaccines
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(see Yaqub, 2017b). However, observations from clinical trials helped to overcome this weakness by
providing a scientific explanation to this failure. The technological answer to cope with the latter came
from the basic knowledge generated when liposomes were used as a research technology. As suggested
in Yaqub (2017b), the characteristics of the testing activities and their related difficulties influence
the type of design developed. The results show that difficulties characterizing R&D activities tend to
expand the scope of the knowledge base to non-medical areas but also rely on inisghts from existing
complementary medical technologies to innovate.
5.2.1 Assessment stage in clinical trials and expansion of the knowledge base
After positive results in preclinical testing, conventional liposomes entered in clinical trials in 1987 to
provide a new type of chemotherapy against cancer. Reaching clinical settings, conventional liposomes
exhibited a limited therapeutic efficiency in terms of stability and targeting power. As a consequence,
research efforts shifted in a competing direction and created the need for scientific explanations about
this unexpected failure (Barenholz, 2012). Considering the uncertainty about the behaviour of li-
posomes in human bodies, the medical researchers involved in clinical trials decided to observe in
real-settings which design was the most appropriate by injecting a competing formulation used as a
control group: the Stealth liposomes. Stealth liposomes were the result of new advances in the field of
new polymers (PEG) in the late 1980s and were combining interesting properties for drug delivery (see
clusters B on Figure 8). The lack of consensus in the community due to contrasting results observed
in animal models could not lead the selection of an appropriate design. Clinical learning removed this
uncertainty by providing insights about the potential factors responsible for the lack of conventional
liposomes stability.
Figure 8a illustrates the re-orientation of search in a new direction thanks to a better understanding
of the clearance mechanism associated to the conventional design coming from clinical learning (see
node 81 on Figure 8a). This finding was then checked in the lab: covering the liposome surface with
PEG makes them “invisible” in the blood circulation, avoiding their clearance (see node 83 on Figure
8a). The hybridization of knowledge from the field polymers with the ongoing liposome knowledge
base (see the distinct trajectory linked to polymers on Figure 8b and cluster B on Figure 8a) marked
a turning point in adapting liposomes to chemotherapy. This new formulation known as Stealth
liposomes pushed the efforts in a new direction and led to the first market approval.
5.2.2 Feedback stage: new scientific questions and specialization of designs
Stealth liposomes were used to achieve the first accelerated market approval - Doxil R© - which aims
at fighting against an orphan form of cancer (see cluster C on Figure 8a). After its market approval,
several observations from clinical practice showed that stealth liposomes tend to cluster around the
tumour cell without merging with it (see cluster E on Figure 8a). This observation relaunched a fierce
debate about the conception of liposomal chemotherapy, opposing the advocates for passive vs active
targeting. In absence of scientific knowledge to rationalize the type of design to favor, both approaches
co-evolve and are illustrated through different specialized designs. Regarding passive targeting ap-
proaches, new formulations of liposomes chemotherapy are developed: either with new compounds
in anticancer chemotherapy, or expanding the use of existing formulations to other diseases areas
(see clusters D on Figure 8a and 8b). The underpinning problems to solve in this approach rely on
different combinations of knowledge, more clinical oriented for new uses beyond chemotherapy while
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new anticancer compounds seem to benefit from scientific insights without applied experimental ori-
entation. In terms of active targeting, different designs emerge which aim at concentrating the action
of liposomes to tumour cells (see clusters E and E-F). They can be categorized in two main cate-
gories through “immunoliposomes”25 and liposomes with controlled released features. As mentioned
in section 5.1.2, basic knowledge generated during the first career of liposomes (here, realm of ligand
and antibodies applied in tumourous cells markers (Weinstein, 1987)) provided the building blocks to
create active targeting liposomes. The second type of design with controlled release features rely on
different strategies (e.g. breaking the liposomes membranes with ultrasounds, or temperature shocks),
related to basic knowledge accumulated when liposomes were used as a research technology (i.e. pH,
gradients, temperature properties)26. In both designs, these bodies of basic knowledge generated
when liposomes were still cell models were used as “background knowledge” (Pavitt, 1998) to guide
the search via new combinations of these existing bodies of knowledge. This specialization pattern
echoes the results found in the case of stents, in which complementary technologies played a leading
role in influencing the rate and direction of new specialized medical applications (Mina et al., 2007).
Besides new drugs, several diagnostic tools (e.g. Magnetic Resonance Imagining, Computer Tomog-
raphy) shaped the influence of new uses combining therapeutic and diagnostics properties (see cluster
E-F on Figure 8b). The merger of the pharmaceutical and diagnostic trajectories echoes another study
(Barberá-Tomás & Consoli, 2012) in which combining technological features was the main answer to
cope with radical uncertainty.
6 Discussion
The previous sections show the importance of clinical learning and of the initial bodies of knowledge
accumulated during the first career of liposomes as research technologies. The results shows that
these distant bodies of knowledge sequentially helped overcoming the issues linked to replication in
the lab in order to innovate. In this respect, Blume (2002) underlines the crucial role played by the in-
terorganizational structure (e.g. academia, industry, and medical practitioners) in order to ensure the
provision of complementary resources and skills to innovate. However, the collaboration within this
interorganizational structure can also be hampered by: disagreements about a specific purpose, the
divergence, or conflicting needs between this set of heterogenenous actors. Blume (2002) talks about
a medical technology having a “non-conformist career”, in which the intensity of knowledge flows is
reduced due to the divergence among medical actors about the “vision” related to a given medical
technology. As a consequence, the feedback mechanisms between science, technology, and clinical
learning slow down. This lack of dynamic is responsible for fragmenting knowledge and reducing
the chance to innovate. In line with Blume (2002), different studies have illustrated the importance
of institutions in standardizing and in coordinating the testing efforts to avoid the fragmentation of
knowledge across different actors (Yaqub & Nightingale, 2012; Yaqub, 2017b,a). By creating research
infrastructure (Nightingale, 1998), specific institutions ease the accumulation of knowledge and the
alignment of visions across a wide range of actors. However, in this study, no centralized institution
emerged in order to coordinate the efforts across disciplines and organizations. To explain this pe-
culiarity, the next sections shed light on the factors which explain why clinical feedback have been
fostered and how federal regulation influenced the standardization of testing activities.
25Liposomes coated with ligands or antibodies.
26See Barenholz (2012) for more details, or the following patent application for an illustration US5192549A
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6.1 Acceptance and demand for an alternative treatment
The changing career of liposomes was also explained by the wide acceptance received from medical
practitioners. The delivery of liposomal chemotherapy did not modify the clinical routine used (in-
jection) and the existing standard to evaluate the treatment success (e.g. tumour shrinkage). By
following the same clinical routine, the introduction of liposomal chemotherapy did not put in doubt
the role of oncologists in treating cancer. Innovation did not legitmize another rival medical spe-
cialty in treating cancer which could have been a barrier of adoption (Gelijns & Rosenberg, 1995).
By proposing a medical solution with quality-enhancing properties, innovation has thus a “status-
enhancing” power within the oncologist community (Geljins & Rosenberg, 1999).
The acceptance of the solution among practitioners helped to foster the feedback coming from the
clinical context to the lab. The initial ties with clinical practitioners in the 1970s, combined with the
first clinical success participated in sustaining a demand for chemotherapeutic approaches focused on
reducing side-effects. The alignment of “visions” from the lab to the benchside influenced the rate and
the direction of efforts by creating a demand for invention. Since technological users were also tightly
connected with technological producers, aligning visions among a wide range of scientists and medi-
cal practitioners created an interorganizational structure to foster feedback across different settings.
While research efforts in the lab were impossible to perfectly replicate, the efforts more downstream
were to some extent standardized due to the specific guidelines that follow anticancer drug develop-
ment. The variability of the results remains but the rules of anticancer drugs development ease the
entry of liposomes in clinical settings.
6.2 Standardizing efforts: testing and proof of concept
Drug development is an expensive process due to the intensive period of testing activity in pre-
clinical and clinical settings. The types of tests involved are heavily regulated by national agencies,
such as the Food Drug Administration in the USA. Anticancer drug development is particularly
concerned by these proofs of concept due to the nature of the compounds involved. As mentioned
earlier, using chemical compounds to kill cancerous cells implies a trade-off between therapeutic
benefits (e.g. tumour shrinkage) and the toxicity issues linked to this type of molecule. The risk-
benefits balance is measured by specific guidelines and evaluated along a sequence of testing from
the most simplified conditions to the more complex ones (i.e. cells, rodents, dogs, and humans).
The inputs and protocols to conduct such testing activities are highly regulated and standardized
(Narang & Desai, 2009). Despite the absence of an institution to govern and to standardize the
testing activities, the regulation framework provided the rules to standardize experiments at a later
stage of medical application developments and eased the entry of liposomes in clinical trials. Doing
so helped in selecting the most promising technological avenues and participated in deepening the
scientific mechanisms explaining the behaviour of some designs.
Liposomal formulations did not lead to additional complex testing guidelines, except the emergence of
a test in vitro to demonstrate their therapeutic benefits (Narang & Desai, 2009). Moreover, most of
the formulations relied on drugs which were already well-known (cytotoxic compounds) which reduced
the development costs by being off-patents and requiring less extensive testing than new compounds
(Narang & Desai, 2009). Finally, the decision to conduct clinical trials in the context of orphan disease
was also responsible for reducing the cost of development (e.g. lower amount of patients involved in
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clinical trials, subsidy from the State to partially cover the cost of development). The latter established
the feasibility of the solution as a new way to deliver chemotherapy. Even if clinical knowledge could
be accumulated, a dialogue must be established across heterogeneous actors to be able to combine
knowledge to innovate. The next section provides some insights about how the feedback mechanisms
have been chanelled across disciplines and settings.
6.3 Fostering feedback across settings via an instrumental community
The use of liposomes as a research technology has been a driving force to combine insights from
various scientific disciplines. Even if the scientific questions raised across fields differed, the shared
use of liposomes as research technologies acted as a medium for communicating across fields (Shinn &
Lamy, 2006). The research efforts were organized around a technique linked to the use of liposomes and
not in a disciplinary fashion. By experimenting with the same research technology, the members of the
instrumental community built, developed, and popularized the latter among a wide range of scientific
disciplines (Mody, 2011). Breaking down the disciplinary and/or institutional boundaries has been
described as the hallmark of medical innovation (Gelijns & Rosenberg, 1995). Rosenberg (1992) and
Rosenberg (2009) suggest that scientific instruments can play a leading role in overcoming disciplinary
boundaries. Scientific instruments represent carriers to transfer know-hows across scientific fields
(deSolla Price, 1984; Rosenberg, 2009): on the one hand, by adopting a new instrument, a given
researcher must acquire a new set of practices and skills linked to its use. On the other hand, learning
by using in experiments generates reliable knowledge about how does a given instrument, or research
technology, work under certain simplified conditions (Nelson, 2008). Instruments are good subjects
for experimentation because they are in theory “amenable to control, and replication” (see Nelson,
2008, :495).
Moreover, the involvement of the founding fathers of the field in establishing the career of liposomes
as a medical technology helped coping with numerous technological failures (see Blume (2002) for a
similar discussion). Since the research community was structured around them, they constituted a sort
of “hub of knowledge” at crossroads between numerous scientific fields, experimental, and institutional
settings. They became de facto an important channel to diffuse the knowledge accumulated across
different settings, fields, and communities all united by the use of the same technology. The founding
fathers have played a leading role in organizing the research efforts and acted as boundaries spanners.
As suggested in Blume (2002), the early orientation of the research efforts towards medical applications
kept the research efforts focused in the same direction. The establishment of a dedicated research
group in clinical settings in the 1970s has been determinant in initiating a dialogue between the bench
and the bedside (Gregoriadis, 2018).
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7 Conclusion
The study outlines the impact of the limited guidance from scientific research on the medical inno-
vation process. The lack of replicability in experiments was responsible for creating a long process
of trial and errors in different experimental settings to adapt the function of liposomes as a new way
to deliver chemotherapy. In absence of guidance from science, the migration of technological capabil-
ities from experimental research in which liposomes were used as a research tool and other medical
applications were crucial. The lack of replication was responsible to maintain a strong degree of path-
dependency with the bodies of knowledge accumulated for distinct uses. The study shows thereby
that the characteristics of experimental research influence not only the design features of technologies
(Yaqub, 2017a) but also the scope of the knowledge base. Like for medical devices, the knowledge
base of pharmaceuticals can encompass non-medical areas and refinement of the technology be eased
with complementary technologies (Mina et al., 2007). The lack of replication was responsible to main-
tain a strong degree of path-dependency with the bodies of knowledge accumulated for distinct uses.
The tacit stock of knowledge which remained embodied in researchers who performed experiments
gave them a comparative advantage to adapt the function of liposomes. The knowledge accumulated
in different experimental settings was chanelled through an instrumental community. The common
purpose of developing liposomal chemotherapy and use of liposomes helped to cross disciplinary bar-
riers. Considering the nature of the problem at hand (e.g. understanding the fundamental behaviour
of liposomes in the body to deliver chemotherapy), one can expect that the majority of the patents
with author-inventors benefited from academic inventors’ expertise. As suggested in Rosenberg (1992,
2009) the role of academic research in diffusing and adapting the use of scientific instrumentation can
be seen as a “social rate of return to society”. The importance of academia as innovator is currently
underestimated in the literature and focuses mainly on complementarity with the private sector Arora
& Gambardella (1995).
The study contributes to the increasing burst of medical innovation literature which highlights the
importance of experimental learning to innovate (see Yaqub & Nightingale, 2012; Consoli et al., 2016;
Yaqub, 2017a,b). Despite the absence of dedicated institutions in governing the testing activities,
the study illustrates the importance of the federal regulation in easing the access to clinical learning
and the role of the founding fathers in coordinating efforts. The study provides new measures to
differentiate between the different contexts in which knowledge was accumulated (i.e. upstream in
the lab, preclinical, and clinical settings). Doing so, the study suggests that science, technology, and
clinical learning played a leading role but in a sequential fashion rather than through continuous
feedback (Gelijns & Rosenberg, 1994). It extends what was suggested in the case of vaccines in Yaqub
(2017a) by showing that clinical trials are more than a selection tool. Clinical trials represent a source
of scientific and technological answers which in this case, expanded the scope of the knowledge base
to cope with the lack scientific guidance. Despite its novelty, the methodology suffers from several
caveats. The definition of the “in vitro” testing regime is based on the specific definition of liposomes.
Additional efforts will be needed to adapt the delineation of publications to other medical technologies.
Moreover, the availability of the patent data underestimated the importance of economics of scope
between experimentation and technologies in the first years of the analysis. The scope of the results is
also by definition limited to the selected case. However, the study suggests some implications regarding
the organization of the medical R&D. The study illustrates the importance of a shared “collective
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vision” in crystallizing expectations (Blume, 1995), but also to mobilize efforts and resources across
the large range of actors involved over the medical innovation process. More attention should be
dedicated to the training of bio-scientists and physicians to ensure a dialogue between the bench and
the bedside. Policy initiatives to align actors’ visions and practices should be favoured to increase the
chances to innovate (see the NIH support in the case of LVAD development in Morlacchi & Nelson,
2011). Scientific funding needs also to evolve to take into account the validity of the research results
and not only the capacity to launch scientific papers. Some steps in this direction have been done in
the context of cancer with replication grants and a dedicated initiative (e.g. Reproducibility Project:
Cancer Biology). Doing so would shift the debate from funding science due to market failures to
building skills in order to tackle complex technological problems (Pavitt, 1991).
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Appendix
Sampling Publications: combining PubMed and Web of Science
The following keywords has been to used to delineate the set of publications related to investigations
linked to the use of liposomes in cancer-related applications:
("Liposomes"[MeSH] OR "Liposomes"[Pharmacological Action] OR
"Phospholipids"[Mesh] OR "SPI-77,liposomal"[Supplementary Concept])
AND
("Antineoplastic Agents"[Pharmacological Action] OR "Antineoplastic Protocols"[MeSH] OR "genes,
Tumor Suppressor"[MeSH] OR "early detection of cancer"[MeSH] OR "cancer vaccines"[MeSH] OR
"chemotherapy, cancer, regional perfusion"[MeSH] OR "neoplasms"[MeSH] OR "enhanced permeability
retention" [all fields])
The list of PMID fitting this criteria has been downloaded on PubMed and used in Web of Science to
maximize the information related to these publications. However, the journal coverage is not perfect
over time which implies some lack of information (e.g. references, affiliations, journal informations)
in the 1980s and the 1990s.
Figure 9: Overlap between PubMed and Web of Science over time
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Partitioning between scientific knowledge
The different types of knowledge involved have been distinguished based on the type of conditions
under which studies were conducted: in vitro, in vivo or clinical settings. The limited number of in
vitro studies justified the use of additional Medical Subject Headings (MeSH) linked to the initial use
of liposomes as research technologies. Both information is available on PubMed and has been added
by NIH librarians specialized in biomedical literature. Contrary to the use of keywords by author,
the MeSH and publication types on PubMed represent a more objective measure to characterize the
contents of a given study. The publication types and Medical Subject Headings available on PubMed
allows to disentangle between them:
Table 4: Delineation between knowledge accumulated in different medical R&D contexts
Testing Regimes MeSH, Publication types
In vitro (green color) Membranes, Artificial; Membrane Lipids;
Cell Membrane; Membranes; Phospholipids; Lipid Bilayers (MeSH)
In vivo (yellow color) mice, rats, dogs, primates (Publication type)
Clinical (red color) clinical trials, phase I to randomized clinical trials,
validation studies, cases report, evaluation studies,
multicenter and observational studies (Publication type)
Publications which did not fit to this taxonomy were assumed to refer to non-experimental knowl-
edge in which liposomes did not play a leading role as research technologies (in grey). In case of
overlap between the different criteria, a hierarchy from the most complex to the most abstract papers
was used to define the context in which knowledge is produced.
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Table 5: List of key publications from the subnetwork
Nodes Publication
1 Gregoriadis (1973)
4 Bangham (1968)
10 Bosmann (1971)
11 Gregoriadis & Ryman (1971)
12 Gregoriadis & Ryman (1972)
17 Gregoriadis & Buckland (1973)
21 Papahadjopoulos et al. (1974)
27 Papahadjopoulos et al. (1975)
31 Poste & Papahadjopoulos (1976)
32 Mayhew et al. (1976)
34 Gregoriadis et al. (1977)
36 Juliano & Stamp (1978)
43 Olson et al. (1979)
55 Yatvin (1982)
60 Weinstein & Leserman (1984)
68 Kabalka et al. (1987)
75 Gabizon et al. (1989)
76 Holmberg et al. (1989)
78 Goren et al. (1990)
79 Klibanov et al. (1990)
81 Gabizon et al. (1991)
83 Lasic et al. (1991)
86 Vaage et al. (1992)
102 Uziely et al. (1995)
109 Muggia et al. (1997)
119 Drummond et al. (1999)
124 Gabizon (2001b)
125 Gabizon (2001a)
135 Gabizon et al. (2003)
138 Alberts et al. (2004)
142 Torchilin (2005)
153 Drummond et al. (2008)
160 Deckers & Moonen (2010)
162 Lindner & Hossann (2010)
163 Hossann et al. (2010)
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Table 6: List of patents from the subnetwork
Layers of efforts US Patent Number
1 6096336
2 5817334 5827533 5874105 5882679 5935553 5985246
5997898 6001335 6033645 6071495 6117414
5628936 5643600 5662957 5705187 5770222 5776429
5804162 5804216 5814599 5830430 5846551 5853752
3 5874062 5962015 6039960 6040295 6056938 6120751
5364633 5376380 5376452 5405615 5415869 5439967
4 544384 5445813 5474848 5542935 5580575 5585112
5620689 5686102 6004534 6015576 6117449
5165994 5190822 5209720 5213804 5219538 5234767
5252263 5260065 5264221 5271928 5316771 5334381
5 5380519 5422120 5527528 5534241 5552155 5576016
5762904
4863739 4917951 4942038 5000960 5013556 5019392
6 5032457 5059421 5077056 5088499 5104736 5123414
5188837 5192549 5204112
4725442 4737323 4753788 4837028 4839111 4853228
7 4855090 4873088 4877561 4880635 4885172 4898735
4906477 4911928 4921706 4946683 4963363
8 4425334 4429008 4610868 4622219 4673567 4708861
4769250 4938947 5283067
4460560 4544545 4603044 4619794 4721612 4731210
4761288 4762720 4776991 4781871 4789633 4880634
9 4920016 5100662 5160669 5198224 5891465 5910306
5948435 6015575 6017556 6042846 6083513 6120794
4310505 4310506 4356167 4394448 4438052 4460577
4485054 4515736 4522803 4529561 4588578 4608211
10 4744989 4772471 4915951 5019174 5141751 5490985
5605704 5733572 5736157 5855911 5885613 5919466
4145410 4148876 4217344 4224179 4229360 4235871
11 4241046 4247411 4308166 4377567 4532089 5328628
4186183 3993754 3683066 3663685 3522346 3663687
4086330 4115536 3663686
4016100 4053585 4089801 4193983 3069370 3607776
12 3692899 3686701 3041289 2949403 2853423 3630920
3932657 1959930 3361680 3549382 2658020 3060030
3012888 3804776 3937668 3173878
3335053 2756178 3590123 3697644 3471624 3533955
13 3535427 3660566 3835169 3056728 3780195 3579633
3752886 3755557 3492399 3594476 3376199 3608066
3384544 3715432 3887698 3317393 3336155 3849546
3882224 3949065 3996345 4104029
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